Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 8/20 | 0.41 |
| ▸ | CA2 | P00918 | 8/20 | 0.41 |
| ▸ | CA9 | Q16790 | 7/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | CA3 | P07451 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 2/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27815332 | 0.98 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL4280442 | 0.98 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL8432808 | 0.98 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL10384072 | 0.98 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL1817035 | 0.98 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL4275678 | 0.98 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL4271916 | 0.98 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL4275158 | 0.98 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| Bromide SCHEMBL28696426 | 0.89 | ALDH1A1 (0.47) | DNM1ALDH1A1 | |
| SCHEMBL6577557 | 0.89 | DNM1 (0.43) | DNM1MEN1KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1766094-A2 | INFLUENZA VIRUS VACCINE COMPOSITION AND METHOD OF USE | Vical Incorporated (US) | 2007-03-28 | — | — | EP | claimed |
| EP-1575505-A4 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST BACILLUS ANTHRACIS INFECTION | VICAL INC (US) | 2007-01-24 | — | — | EP | claimed |
| WO-2005116270-A2 | INFLUENZA VIRUS VACCINE COMPOSITION AND METHOD OF USE | VICAL INCORPORATED (US) | 2005-12-08 | — | — | WO | claimed |
| EP-1575505-A2 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST BACILLUS ANTHRACIS INFECTION | Vical Incorporated (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1575505-A3 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST BACILLUS ANTHRACIS INFECTION | Vical Incorporated (US) | 2005-09-01 | — | — | EP | claimed |
| WO-2004024067-A2 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST BACILLUS ANTHRACIS INFECTION | VICAL INCORPORATED (US) | 2004-03-25 | — | — | WO | claimed |
| CN-114053225-B | High-efficiency low-toxicity cationic liposome with good stability for gene delivery and application thereof | 浙江大学 | 2023-03-28 | — | — | CN | disclosed |
| EP-3368670-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS | Editas Medicine, Inc. (US) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017075475-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS | EDITAS MEDICINE, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| EP-1278551-A2 | COMPOSITIONS AND METHODS FOR (IN VIVO) DELIVERY OF POLYNUCLEOTIDE-BASED THERAPEUTICS | VICAL INCORPORATED (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001080897-A2 | COMPOSITIONS AND METHODS FOR IN VIVO DELIVERY OF POLYNUCLEOTIDE-BASED THERAPEUTICS | VICAL INCORPORATED (US) | 2001-11-01 | — | — | WO | disclosed |